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Abstract: Osteoarthritis (OA) is a pathological degenerative condition of the joints that is
widely prevalent worldwide, resulting in significant pain, disability, and impaired quality of
life. The diverse etiology and pathogenesis of OA can explain the paucity of viable preventive
and disease-modifying strategies to counter it. Advances in genome-editing techniques may
improve disease-modifying solutions by addressing inherited predisposing risk factors and the
activity of inflammatory modulators. Recent progress on technologies such as CRISPR/Cas9 and
cell-based genome-editing therapies targeting the genetic and epigenetic alternations in OA offer
promising avenues for early diagnosis and the development of personalized therapies. The purpose
of this literature review was to concisely summarize the genome-editing options against chronic
degenerative joint conditions such as OA with a focus on the more recently emerging modalities,
especially CRISPR/Cas9. Future advancements in novel genome-editing therapies may improve the
efficacy of such targeted treatments.
Keywords: osteoarthritis; CRISPR/Cas9; miRNA; genome editing
1. Introduction
Osteoarthritis (OA) is a chronic disease affecting the joints of the body, especially the weight-bearing
joints, chiefly the knees, hips, shoulders, and spine. OA is the most common type of degenerative
arthritis, affecting over 30 million Americans [1]. It is also the second most expensive disease to treat in
the US, costing $139.8 billion in 2013 [2]. As the fifth leading cause of disability in the US, OA has a
significant impact on the quality of life.
In 2017, the Centers for Disease Control (CDC) published results on the prevalence of
doctor-diagnosed arthritis from 2013 to 2015, including 54.4 million adults, nearly half of whom
had activity limitations attributable to arthritis [3]. More alarmingly, as our US population ages,
the number of cases is projected to increase to 78.4 million, or 25.9% of the population, by 2040 [4].
According to the World Health Organization (WHO), the United Nations has categorized OA as
a priority disease in need of research into potential therapies. Given that between 2015 and 2050,
the proportion of the world’s population over 60 years old will nearly double from 12% to 22%,
an estimated 130 million people will suffer from OA worldwide (WHO, 2018).
The progression of OA includes the degradation of the hyaline articular cartilage at the ends
of the articulating bones of the synovial joints. The articular cartilage, when healthy, functions to
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resist compression, prevent bone–bone contact, and maintain a low-friction surface [5]. Damaged joint
articular cartilage, on the other hand, cannot perform the necessary functions [6]. Additionally,
the repair of the damaged articular cartilage is a challenging issue, due in part to its avascular
nature and its limited ability to heal by itself [5–7]. This often results in the formation of fibrocartilage,
which lacks the ideal biomechanical characteristics needed to withstand the compressive stress imposed
on the synovial joints during articulation and load-bearing [8,9].
Normally, synovial joints in the body move effortlessly, gliding across each other [10]. This is due
in part to the unique properties of the synovial fluid secreted by the cells of the inner lining of the joint
capsule and its ability to reduce the friction that is generated by movement at the joint surfaces [5,10,11].
The articular hyaline cartilage at the joint surfaces maintains the proper structure, function, and stability
of the synovial joints [10]. Unfortunately, chondrocytes have limited potential for replication, a factor
that contributes to the limited intrinsic healing capacity of cartilage in response to injury. Chondrocyte
survival depends on an optimal biochemical and mechanical environment [5,12], Localized stress,
wear, and tear lead to degeneration of the cartilage and may also lead to the activation of osteoblasts,
resulting in new anomalous bone formation [13,14] (Figure 1). Opportunities for prevention or slowing
the progression of degradation may exist if the disease is detected during its early stages. If left
untreated, however, OA can lead to complete loss of joint cartilage, severe pain, restricted range of
joint and limb movement, and altered reshaping of the bones within the joint [15–17].
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Figure 1. Articular joint structure. (a) Bone and cartilage of a healthy tibiofemoral joint (b) Simulation
of cartilage degeneration and bone spur formation in an osteoarthritic knee.
OA, characterized by joint stiffness, tenderness, swelling, and pain, is not a single disease per se [14].
It is, rather, a complex disease consisting of a group of conditions with multiple pathways that all
result ultimately in progressive, irreversible joint failure as the outcome. Many susceptibility factors
play a part in the pathogenesis of OA, such as age, gender, and weight [18–20]. Old age, female gender,
repetitive joint stress, injury, joint laxity, high body weight, and osteoporosis all contribute to OA [21,22].
With t e increasing life sp n of the population in addition to the epidemic of obesity, the number of
people aff cted by joint degeneration is expected to increa e substan ially [23–25]. S vere OA can
prevent a person from bei g able to work, especially if their work involves putting stress on a specific
joint for an extended duration. OA can result in significant physical, mental, emotional, and social
challenges as well [26–28].
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Despite nonsurgical and surgical interventions, there is currently neither a cure for this disease nor
a means to halt its inevitable progression [22,29]. Autologous chondrocyte transplantation has shown
promise in clinical treatment, however, the process involves the harvest, culture, and transplant of cells
grown in a monolayer (2D culture) [30–33]. Under these culture conditions, the risk of dedifferentiation
of the chondrocytes and an altered phenotype is a major concern of tissue engineering [34].
2. Current Treatment Options and Limitations
The progressive erosion of articular cartilage is a prevalent symptom of OA [35]. Articular cartilage
is made up of chondrocytes embedded within a collagenous extracellular matrix (ECM) [36]. Disruption
of the articular cartilage prevents pain-free movement and affects the load-bearing abilities of the
joint. Current treatments for OA can include intra-articular joint injections of steroids and arthroscopic
lavage with debridement; however, these may have short-term benefits without long-term benefit
to the cartilage [22,37,38]. Anti-inflammatory and analgesic drugs may help to address some of the
symptoms of OA, but they do not tackle the fundamental pathologies involved in the inexorable
degenerative process, in addition to having significant side effects associated with prolonged use [39–42].
Surgery and joint replacement, if possible in the early stages of OA, are expensive and may need to be
performed multiple times during an individual’s life [22,43]. Alternative modalities of treatment may
well be helpful in the short term, but may not be a sustainable strategy for OA treatment and potential
prevention [44,45].
The best way to combat the root cause of joint degeneration in OA may be through the exploration
of the various possibilities that genome editing offers [46,47]. There is increasing evidence that
genetic and epigenetic modifications play a substantive role in OA; however, it has been difficult to
separate the individual effects from the combined effects of genetic and environmental factors acting
together to cause progressive joint degeneration [48–51]. Characterizing and analyzing the genetic
factors underpinning the pathology of OA may provide viable options for the diagnosis, prognosis,
and development of novel treatment targets for future personalized biological therapies.
3. CRISPR/Cas
Several gene therapy systems such as viral, engineered scaffold, and other approaches hold
promise [52]. However, while such systems hold promise, the advantages are offset by some potential
disadvantages. Here we focus on the CRISPR/Cas9 system, a very powerful gene therapy tool.
CRISPR/Cas is a novel, versatile, and promising genome-editing technique that is opening up
new avenues and possibilities in the effective treatment of OA [53] and other degenerative joint
diseases [54,55]. CRISPR is an acronym for “clustered regularly interspaced short palindromic repeats”,
discovered through investigation of the prokaryotic adaptive immune system. It was identified as an
effective system used by bacteria and archaea to remember infecting agents such as phage viruses and
destroy them upon subsequent exposure, similarly to the memory cells in the human immune system.
When paired with different proteins, specifically enzymes such as Cas, that are produced naturally
by the prokaryotic cells, the CRISPR system can be used to make deletions, insertions, substitutions,
or other changes at specific sites of the prokaryotic and eukaryotic genome [56,57]. From finding a cure
for cancer, to treating sickle-cell disease, to growing drought- and pest-resistant crops, CRISPR has
many exciting possibilities and potential in several fields [58].
The prokaryotic CRISPR/Cas system has three main components: a Cas nuclease, a crRNA
(CRISPR RNA), and a tracrRNA (trans-activating crRNA). In bacterial cells, the CRISPR/Cas
system works by recognizing the invading bacteriophage DNA, chopping it up into several pieces,
and incorporating them into its DNA. These CRISPR pieces are then transcribed, generating a crRNA
and a tracrRNA to create a double-stranded RNA structure that can recruit the Cas proteins. When the
offending phage is encountered again, the CRISPR/Cas system is directed to a specific location on the
foreign DNA because of a protospacer adjacent motif (PAM) short nucleotide base sequence which is
upstream of the crRNA targeted sequence. The Cas protein is programmed to be the “molecular scissors”
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of the system which carries out the cutting, splicing, and any other editing that is desired [59–61].
The therapeutic application of CRISPR/Cas is illustrated in Figure 2.
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hondrocytes originate from mesenchymal stem cells [71,72]. Bone-marrow-derived MSCs
(BM-MSCs) have much promise in aiding articular cartilage repair due to their proximity to the
joint, high differentiation capability, and ability to secrete different growth, anti-inflammatory,
and immunomodulatory factors [73–77]. They could affect a clinically relevant improvement in
joint pain and function. Additional studies are needed, however, to demonstrate the efficacy of cultured
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versus noncultured BM-MSCs and the best ways to deliver them into the joint. MSCs derived from
fetal cells also have therapeutic properties, but ethical concerns have been raised about using them
for treatment and therapeutic applications [78,79]. Additional challenges arise due to the potential
of fetal MSCs to differentiate into several different types of cells, which might be more difficult to
control and direct [76,80,81]. The capabilities of MSCs are usually age-dependent. MSCs have a
short lifespan but can secrete paracrine factors that may be beneficial in tissue regeneration [81,82].
In addition to BM-MSCs, MSCs derived from other sites such as adipose tissue can be isolated,
expanded, characterized, and used to regenerate cartilage [83,84]. However, MSCs tend to form
mechanically inferior fibrocartilage instead of the glassy, hyaline cartilage that covers the ends of bones
at articulating joints [85].
5. Extracellular Vesicles
Genome-editing factors, packaged in engineered CRISPR/Cas9 complexes, can be enclosed in
extracellular vesicles (EVs), for delivery to specific target cells [86,87]. EVs are composed of cellular
constituents such as lipids, proteins, RNA, and DNA [86,88]. EVs may cross the blood–brain barrier,
target cells in vivo, and protect their components from degradation in the circulatory system [87,89].
Their function is dependent upon their origin, and EVs derived from MSCs could have the potential
to deliver contents to OA cells [90–93], as shown in Figure 3 [85,94,95]. The use of exosomes as a
nonselective cell system may have limitations, including the delivery of contents to unintended cell
targets. Possible solutions to this challenge include the design of targeted exosomes, as suggested by
Bellavia and colleagues [96].
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Exogenous-cell-based therapy is gaining traction for the regeneration of articular cartilage
over stimulation therapy such as electric stimulation of endogenous cartilage growth factors [97].
Exogenous cell therapy can be done through the delivery of chondrocytes (either autologous or
allogeneic), mesenchymal stem cells (MSCs), or extracellular vesicles [98]. MSCs are used for regenerative
medicine due to their ability to promote regeneration based on environmental signals at sites of injury.
As inhibitors of the immune system and multilineage differentiators, MSCs are an important alternative
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cell source for articular cartilage repair and regeneration [97]. MSCs derived from the synovial membranes
of joints have been shown to be more effective in terms of articular cartilage formation in in vitro studies
when compared to MSCs from other tissues, joint and nonjoint [99,100].
In vitro studies performed in mice showed that microparticles and exosomes, which are EVs
derived from MSCs, exerted similar chondroprotective and anti-inflammatory functions, protecting mice
from developing osteoarthritis and reproducing the main therapeutic effect of reducing symptoms [101,
102]. Thus, a combinatorial approach to the treatment of OA may be feasible.
6. Potential CRISPR/Cas9 Molecular Targets for the Treatment of Osteoarthritis
Cell therapy has great potential to help treat OA, but inflammation can prevent new articular
cartilage from forming after the introduction of stem cells. Inflammation and inflammatory modulators
must be addressed in the treatment of OA, and these inflammatory modulators may serve as targets
for CRISPR/Cas9 strategies [103]. Table 1 identifies potential targets for CRISPR/Cas9 editing and the
laboratories that are making progress in the use of CRISPR/Cas9 techniques in OA treatment.
IL-1β is a pro-inflammatory cytokine secreted primarily by neutrophils. IL-1β induces the
expression of many OA-related genes and other cytokines, including tumor necrosis factor-alpha
(TNFα) [104]. Current OA therapies target TNFα, however, deleterious side effects occur due to TNFα’s
role in facilitating many other functions [105,106]. Human articular cartilage (hAC) exposed to TNFα
displays increased levels of expression of interleukin IL-1β [105,106]. Karlsen and colleagues, in their
2016 study, were able to silence the IL-1β cytokine receptor (IL1-R1) in hACs to determine its effect on
inflammation and the redifferentiation potential of the hACs after exposure to the interleukin IL-1β.
The hACs were isolated from cartilage, and CRISPR/Cas9 was used to knock out the IL1-R1 receptor
and insert a puromycin-resistance gene to allow the selection of the knockout cells. The colonies of
knockout cells were expanded and exposed to recombinant IL-1β and TNFα to assess their response.
The results showed that the addition of recombinant IL-1β increased inflammation to high levels in the
control group, as expected. However, in the knockout group, exposure to recombinant IL-1β did not
cause measurable inflammation. Therefore, the therapeutic knockdown of IL1-R1 in articular cartilage
cells in vitro prior to re-injection into the body may improve cell-therapy results [106].
Table 1. Potential CRISPR/Cas9 molecular targets for CRISPR/Cas treatment of osteoarthritis.
Gene Symbol Gene Name Function Reference
IL1-β Interleukin 1 beta Inflammation
Karlsen, 2016 [106]
Zhao, 2019 [53]
Guilak [73]
IL1-R1 Interleukin 1 beta receptor Inflammation Karlsen, 2016 [106]
BGLAP Osteocalcin Trabecular bone formation Lambert, 2016 [107]
miR-140 Micro RNA 140 Chondrocyte homeostasis Asahara, 2016 [108]
Has2 Hyaluronan synthase 2 Chondrocyte accumulation of aggrecan Huang, 2016 [109]
sTNFR1α Soluble Tumor necrosis factor receptor 1 TNF antagonist Brunger, 2017 [110]
IL1RA Interleukin 1 bets receptor antagonist IL-1 beta antagonist Brunger, 2017 [110]
PRG4 Lubricin Joint lubrication Khakshooy, 2017 [111]
Runx2 Runt Related Transcription Factor 2 Osteoblast differentiation Rice, 2018 [112]
Hrdl E3 ubiquitin-protein ligase hrd-likeprotein 1
Protein turnover and proteasomal
degradation Ye, 2018 [113]
Mmp13 Matrix metalloprotein 13 Tissue degradation Seidl, 2019 [114]Zhao, 2019 [53]
Cx43 Connexin 43 Gap junction protein Varela-Eirín M, 2018 [115]
NGF Nerve growth factor Pain sensitivity Zhao, 2019 [53]
Cbx4 Chromobox 4 Nucleolar homeostasis Ren, 2019 [116]
Foxd1 Forkhead box D1 Transcription factor Fu, 2019 [117]
YAP Yes-associated protein 1 Mechanosensing transcription factor Fu, 2019 [117]
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Recent gene-editing efforts have targeted cellular senescence. Ren and colleagues found that by
targeting CBX4, cellular senescence could be alleviated, with positive outcomes for OA [116]. FOXD1 is
a transcription factor that can be regulated by YAP. Recent research indicates that the upregulation of
FOXD1 by YAP may hold promise for OA treatment by alleviating senescence [117]. Further studies
that focused on connexin 43 modulation were able to demonstrate that the attenuation of cellular
senescence could promote the regenerative capacity of cells and improve tissue quality in OA [115].
Degradative enzymes such as matrix metalloproteinases (MMP) play important roles in joint
health. Seidl and colleagues utilized CRISPR/Cas9 to modify the MMP13 levels in human chondrocytes
and found that by reducing the level of MMP activity, cells were able to accumulate higher levels of the
beneficial type II collagen to strengthen the extracellular matrix of the articular cartilage [114].
7. Additional Emerging Targets for the Treatment of Osteoarthritis Using CRISPR/Cas9
While a significant focus is placed on cartilage and the chondrocytes that maintain articular
cartilage, there is wide agreement that OA is not simply a disease of the cartilage, but rather of the
entire joint, and all of the specific tissue types within the joint play essential roles. Osteocalcin, a small
protein hormone secreted by the osteoblasts of the bone, has been studied recently for its endocrine
functions, which impact several physiological processes. Lambert and colleagues found in their 2016
study that by applying CRISPR/Cas9 technologies to osteocalcin expression, they were able to improve
bone biomechanics and increase the trabecular bone in a rat model system [107].
Additional potential targets for therapy have been identified using CRISPR/Cas9 technology.
For example, CRISPR/Cas9 knockout of hyaluronan synthase 2 (HAS2) in rat chondrocytes demonstrated
the importance of the glycosaminoglycan hyaluronan, for the retention of aggrecan, a proteoglycan
necessary for the functional integrity of the articular cartilage [109]. CRISPR/Cas9 can, therefore,
provide fundamental information about the molecular mechanisms required for healthy joint tissue in
addition to potential use as a direct treatment.
8. Limitations and Future Considerations
The CRISPR/Cas9 system is being used in a wide range of applications and many studies. However,
notwithstanding its meteoric rise in a short period of time and its potential applications in medicine
and beyond, it, like other genome-editing tools, does come with limitations and concerns, ethical and
otherwise. One of these limitations is the effective targeting range, as the sgRNA can only bind to a
region near a specific PAM sequence on the DNA. The PAM sequence for Cas9 is 5′-NGG-3′, where “N”
can be any nucleotide base, but the third base must be G. This can greatly reduce the potential target
locations available to make DNA edits such as insertions or deletions. In experiments conducted by
Nishimasu and colleagues, a Cas9 with a more relaxed preference for the PAM third base resulted
in the recognition of an NGD PAM instead of an NGG PAM requirement. This effectively increased
the potential targets for Cas9 nuclease, as the NGD sequence occurs more frequently in human DNA
than NGG sequences. The engineered Cas9 in this instance had a wider range and increased cleavage
specificity, reducing instances of off-target incisions. The new Cas, termed SpCas9-NG, can bind to A,
G, or T in the 3rd base of the PAM sequence [118].
MicroRNAs (miRNAs), small, non-coding RNA molecules, may help to regulate inflammation,
promote MSC differentiation, and ensure the homeostasis of cartilage [119]. As a key factor in epigenetic
regulation, miRNAs can change the gene expression without modifying the sequence of the DNA
that encodes proteins [120]. This may be a much safer way to modulate gene expression since the
genome sequence does not change, and the gene expression pattern may still be inheritable from one
cell generation to the next [85]. miRNAs may be used in combination with CRISPR/Cas9 and EVs to
design patient-specific approaches to the treatment of OA [103].
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9. Conclusions
Investigators and practitioners the world over are working toward a better understanding of the
basis of degenerative joint diseases such as OA. Devising ways to alter or modify the relevant genes
impacting the joint articular cartilage may lead to the development of successful, safe, and effective
therapies to halt the progress, treat, or even prevent the occurrence of OA and other debilitating
joint disorders in humans. CRISPR/Cas9, MSCs, EVs, and miRNAs may all play key roles in
future treatments.
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